{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T07:10:02Z","timestamp":1749107402886,"version":"3.41.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82104618"],"award-info":[{"award-number":["82104618"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A prospective, single-arm, open-label Phase III clinical trial was conducted across multiple centers in China from April 27, 2020, to June 15, 2021, to assess the efficacy and safety of 10% intravenous immunoglobulin (IVIg) in treating adult immune thrombocytopenic purpura (ITP). Within 7\u00a0days of treatment initiation, the 10% IVIg group exhibited an overall response rate of 87.0%, with 32 patients (46.4%) achieving complete response and 28 patients (40.6%) demonstrating partial response, comparable to the 5% IVIg group. Notably, the median time to achieve a platelet count (PLT) of 50\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L was significantly shorter for the 10% IVIg group at 2\u00a0days (IQR: 2\u20133) versus 3\u00a0days (IQR: 3\u20135) for the 5% IVIg group. Additionally, the 10% IVIg group reached a PLT of 100\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L in 3\u00a0days (IQR: 3\u20134), compared to 5\u00a0days (IQR: 4\u20136) for the 5% IVIg group. Post-treatment bleeding scores significantly decreased, and no significant adverse reactions were reported. This inaugural study highlights the efficacy and safety of 10% IVIg in the urgent management of adult ITP, positioning it as a rapid therapeutic option.\n<\/jats:p>","DOI":"10.1007\/s00277-025-06391-1","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T13:03:30Z","timestamp":1746882210000},"page":"2643-2651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety analysis of China\u2019s first 10% IVIg (RonsenGlob) therapy in treating adult ITP"],"prefix":"10.1007","volume":"104","author":[{"given":"Lijun","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guitao","family":"Jie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ligen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenxian","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanliang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruibin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"issue":"6","key":"6391_CR1","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","volume":"16","author":"S Audia","year":"2017","unstructured":"Audia S, Mahevas M, Samson M et al (2017) Pathogenesis of immune thrombocytopenia. Autoimmun Rev 16(6):620\u2013632","journal-title":"Autoimmun Rev"},{"key":"6391_CR2","doi-asserted-by":"publisher","first-page":"103820","DOI":"10.1016\/j.ebiom.2022.103820","volume":"76","author":"D Provan","year":"2022","unstructured":"Provan D, Semple JW (2022) Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine 76:103820","journal-title":"EBioMedicine"},{"issue":"3","key":"6391_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1055\/s-0039-1684031","volume":"39","author":"S Mithoowani","year":"2019","unstructured":"Mithoowani S, Arnold DM (2019) First-line therapy for immune thrombocytopenia. Hamostaseologie 39(3):259\u2013265","journal-title":"Hamostaseologie"},{"issue":"6","key":"6391_CR4","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1111\/bjh.17872","volume":"196","author":"DJ Kuter","year":"2022","unstructured":"Kuter DJ (2022) Novel therapies for immune thrombocytopenia. Br J Haematol 196(6):1311\u20131328","journal-title":"Br J Haematol"},{"issue":"6","key":"6391_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1517\/14740338.2010.484419","volume":"9","author":"JB Caress","year":"2010","unstructured":"Caress JB, Kennedy BL, Eickman KD (2010) Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf 9(6):971\u2013979","journal-title":"Expert Opin Drug Saf"},{"key":"6391_CR6","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z (2018) Adverse effects of immunoglobulin therapy. Front Immunol 9:1299","journal-title":"Front Immunol"},{"key":"6391_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/CIA.S369574","volume":"18","author":"E Crickx","year":"2023","unstructured":"Crickx E, Mahevas M, Michel M, Godeau B (2023) Older adults and immune thrombocytopenia: considerations for the clinician. Clin Interv Aging 18:115\u201330","journal-title":"Clin Interv Aging"},{"issue":"1","key":"6391_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/hematology.2023000478","volume":"2023","author":"JM Connors","year":"2023","unstructured":"Connors JM, Fein S (2023) How to manage ITP with life-threatening bleeding. Hematol Am Soc Hematol Educ Program 2023(1):254\u2013258","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"13","key":"6391_CR9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2217\/imt-2017-0071","volume":"9","author":"RL Wasserman","year":"2017","unstructured":"Wasserman RL (2017) Gammaplex((R)) 5 and 10% in the treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura. Immunotherapy 9(13):1071\u20131088","journal-title":"Immunotherapy"},{"issue":"4","key":"6391_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1179\/102453309X439773","volume":"14","author":"T Robak","year":"2009","unstructured":"Robak T, Salama A, Kovaleva L et al (2009) Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology 14(4):227\u2013236","journal-title":"Hematology"},{"issue":"2","key":"6391_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2217\/imt-2018-0165","volume":"11","author":"S Apte","year":"2019","unstructured":"Apte S, Navarro-Puerto J, Damodar S et al (2019) Safety and efficacy of intravenous immunoglobulin (Flebogamma((R)) 10% DIF) in patients with immune thrombocytopenic purpura. Immunother\u00a011(2):81\u201389","journal-title":"Immunotherapy"},{"issue":"1","key":"6391_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/tme.12573","volume":"29","author":"O Arbach","year":"2019","unstructured":"Arbach O, Taumberger AB, Wietek S et al (2019) Efficacy and safety of a new intravenous immunoglobulin (Panzyga((R)) ) in chronic immune thrombocytopenia. Transfus Med 29(1):48\u201354","journal-title":"Transfus Med"},{"issue":"19","key":"6391_CR13","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.3346\/jkms.2018.33.e142","volume":"33","author":"J Hong","year":"2018","unstructured":"Hong J, Bang SM, Mun YC et al (2018) Efficacy and Safety of a New 10% Intravenous Immunoglobulin product in patients with primary immune thrombocytopenia (ITP). J Korean Med Sci 33(19):e142","journal-title":"J Korean Med Sci"},{"issue":"4","key":"6391_CR14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1160\/TH03-10-0650","volume":"91","author":"JB Bussel","year":"2004","unstructured":"Bussel JB, Eldor A, Kelton JG et al (2004) IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost 91(4):771\u2013778","journal-title":"Thromb Haemost"},{"issue":"5","key":"6391_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1179\/102453310X12719010991867","volume":"15","author":"T Robak","year":"2010","unstructured":"Robak T, Mainau C, Pyringer B et al (2010) Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam(R) 10%) in patients with immune thrombocytopenia.\u00a0Hematol 15(5):351\u2013359","journal-title":"Hematology"},{"issue":"10","key":"6391_CR16","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1182\/blood-2005-12-019604","volume":"109","author":"S Jarius","year":"2007","unstructured":"Jarius S, Eichhorn P, Albert MH et al (2007) Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptor-independent way. Blood 109(10):4376\u20134382","journal-title":"Blood"},{"issue":"13","key":"6391_CR17","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1182\/blood-2006-05-021568","volume":"108","author":"S von Gunten","year":"2006","unstructured":"von Gunten S, Schaub A, Vogel M et al (2006) Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108(13):4255\u20134259","journal-title":"Blood"},{"issue":"3","key":"6391_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.14740\/jh385w","volume":"7","author":"F Rodeghiero","year":"2018","unstructured":"Rodeghiero F, Woszczyk D, Slama B et al (2018) Efficacy and safety of IQYMUNE(R), a ten percent intravenous immunoglobulin in adult patients with chronic, primary immune thrombocytopenia. J Hematol 7(3):87\u201395","journal-title":"J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06391-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06391-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06391-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:37:28Z","timestamp":1749105448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06391-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6391"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06391-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"8 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol for the clinical study titled \u201cAn Open-Label, Multicenter Clinical Study of the Efficacy and Safety of Intravenous Human Immunoglobulin (pH4, 10%) (Chromatography) in Patients with Primary Immune Thrombocytopenia\u201d (ChiCTR2300069388) and the inclusion of patients treated with the 5% IVIg regimen from a simultaneous national cohort study (ClinicalTrials.gov ID: NCT04645199) were approved by the institutional review boards or independent ethics committees of all participating centers. The study adhered to the principles outlined in the Declaration of Helsinki and the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences). Written informed consent needed was obtained from all participating patients prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The clinical study evaluating 10% IVIg is registered on Chinese Clinical Trial Registry with the registration number ChiCTR2300069388. Additionally, the longitudinal cohort study of 5% IVIg has been registered on ClinicalTrials.gov under the registration number NCT04645199.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial registration"}}]}}